ERBB2 and neoplasm: We also proposed mNeo-Bioscore, an optimized staging system based on Neo-Bioscore, by altering the scoring points of HER2-low tumor, which allowed for the precise prognosis stratification of patients with breast cancer after neoadjuvant therapy.